Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Long-Term Investments (2021 - 2026)

Vaxcyte (PCVX) has 6 years of Long-Term Investments data on record, last reported at $1.0 billion in Q1 2026.

  • On a quarterly basis, Long-Term Investments fell 21.5% to $1.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 billion, a 21.5% decrease, with the full-year FY2025 number at $881.7 million, down 36.46% from a year prior.
  • Long-Term Investments reached $1.0 billion in Q1 2026 per PCVX's latest filing, up from $881.7 million in the prior quarter.
  • Over the last five years, Long-Term Investments for PCVX hit a ceiling of $1.4 billion in Q4 2024 and a floor of $4.0 million in Q3 2022.
  • A 5-year average of $544.1 million and a median of $399.2 million in 2024 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: plummeted 89.99% in 2022, then surged 4138.47% in 2023.
  • Tracing PCVX's Long-Term Investments over 5 years: stood at $26.5 million in 2022, then skyrocketed by 512.73% to $162.7 million in 2023, then soared by 752.93% to $1.4 billion in 2024, then tumbled by 36.46% to $881.7 million in 2025, then grew by 13.88% to $1.0 billion in 2026.
  • Business Quant data shows Long-Term Investments for PCVX at $1.0 billion in Q1 2026, $881.7 million in Q4 2025, and $959.3 million in Q3 2025.